- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01918098
Targin for Non-cancer Pain
A Randomized, Double-blind, Double-dummy, Parallel-group, Multicenter Study to Demonstrate Improvement in Symptoms of Constipation in Subjects With Moderate to Severe Non-malignant Pain Taking Oxycodone Equivalent of ≥10 mg/Day and ≤50 mg/Day as Oxycodone/Naloxone Prolonged-release (OXN) Compared to Subjects Taking Oxycodone Prolonged-release (OXY) Tablets Alone.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Beijing, Cina
- Peking University Third Hospital
-
Beijing, Cina
- Peking Union Medical College Hospital
-
Beijing, Cina
- Beijing Friendship Hospital
-
Beijing, Cina
- Beijing Tiantan Hospital
-
Beijing, Cina
- Beijing Union Hospital
-
Bengbu, Cina
- the First Affiliated Hospital of Bengbu Medical Collage
-
Changsha, Cina
- Xiangya Hospital Central South University
-
Changsha, Cina
- The Third Xiangya Hospital of Central South University
-
Changsha, Cina
- The thrid Xiangya Hospital of central south university
-
Chengdu, Cina
- West China Hospital
-
Chongqing, Cina
- Daping Hospital
-
Chongqing, Cina
- South West hospital
-
Fuzhou, Cina
- Fuzhou General Hospital
-
Guangzhou, Cina
- The third affiliated hospital sun yat-sen university
-
Guizhou, Cina
- Guizhou Provincial People's Hospital
-
Harbin, Cina
- The Second Affiliated Hospital of Harbin Medical University
-
Jinan, Cina
- Shandong Provincial Hospital
-
Shanghai, Cina
- Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
-
Shanghai, Cina
- Shanghai Changhai Hospital
-
Shanghai, Cina
- Zhongshan Hospital Fudan University
-
Shanghai, Cina
- Shanghai Sixth People's Hospital
-
Shantou, Cina
- The First Affiliated Hospital of Shantou University Medical College
-
Shenyang, Cina
- The General Hospital of Shenyang Military
-
Wuhan, Cina
- The Central Hospital of Wuhan
-
Wuhan, Cina
- Tongji Hospital
-
Wuhan, Cina
- Union Hospital Tongji Medical College
-
Xuzhou, Cina
- The Affiliated Hospital of Xuzhou Medical University
-
Zhejiang, Cina
- Second Affiliated Hospital of Zhejiang University
-
-
Guangdong
-
Guangzhou, Guangdong, Cina
- Guangzhou First People's Hospital
-
Shan Tou, Guangdong, Cina
- Second Affiliated Hospital of Shan Tou University Medical College
-
-
Hebei
-
Shijiazhuang, Hebei, Cina
- Hebei General Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Screening Inclusion criteria:
- Males or females, 18 years of age or older
- Clinical diagnosis of musculo-skeletal pain for 4 weeks or longer with non-malignant pain etiology at Visit 1. Possible etiologies are conditions related to intervertebral disc disease, spondylolisthesis and osteoarthritis; other similar non-malignant diseases are also eligible.
- Patients with non-malignant pain that require around-the-clock opioid therapy (oxycodone equivalent of ≥10 mg/day and ≤50 mg/day) who are likely to benefit from WHO step III opioid therapy for the duration of the study
- Patients who have been already treated with NSAIDs at least 2 weeks before enrolment are also eligible, but they should rate their pain (Pain Intensity Scale -"average pain" over the last 24 hours) as ≥4 on 0-10 scale."
- Subjects are either taking opioid medication or willing to take opioids to treat their pain
- Patients who are willing to use adequate and reliable contraception throughout the study. Highly effective methods of birth control are defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilization, implants, injectable, combined oral contraceptives, some IUDs (intrauterine Device, hormonal), sexual abstinence or vasectomized partner
- Subjects willing and able to participate in all aspects of the study, including use of oral medication, completion of subjective evaluations, attending scheduled clinic visits, completing telephone contacts, and compliance with protocol requirements are evidenced by providing written informed consent
Subjects taking pre-study, non-opioid analgesics, and all other concomitant medications, including those medications for the treatment of depression and are considered necessary for the subject's welfare, and are anticipated to remain stable throughout the double-blind period of the study, and are to be continued under the supervision of the investigator, are eligible.
- Patients who have been already treated with NSAIDs at least 2 weeks before enrolment are also eligible, but they should rate their pain (Pain Intensity Scale -"average pain" over the last 24 hours) as ≥4 on 0-10 scale.
Criteria for entry to the Double-Blind phase:
- Subjects continue to satisfy screening criteria outlined in the protocol
- Subject's OXY dose is between 10-50 mg/day
- Subjects who rate their pain (Pain Intensity Scale -"average pain" over the last 24 hours) as≤4 on 0-10 scale with less than or equal to two doses of Morphine Sulfate tablets rescue medication per day for either the last three consecutive days or four of the last seven days
Subjects who have constipation induced, or worsened by their opioid study medication, as shown by:
- The subject's medical need for regular intake of laxatives to have at least 3 bowel evacuations per week, or having less than 3 bowel evacuations per week when not taking a laxative, respectively and
- The subjects' constipation was considered to be induced, worsened or maintained by their current study opioid medication and
- BFI value > 30.
- Subjects demonstrate compliance with laxative use, and completing appropriate and legible daily diaries
- Subjects taking daily fibre supplementation or bulking agents are eligible if they can be maintained on a stable dose and regimen throughout the study, and in the investigator's opinion are willing and able to maintain adequate hydration.
Screening Exclusion criteria:
- Females who are pregnant (positive β-hCG test) or lactating
- Any history of hypersensitivity or with any contraindication to oxycodone, naloxone, bisacodyl, or related products
- Subjects currently taking the equivalent of > 50 mg/day Oxycodone PR
- Evidence of clinically significant cardiovascular, renal, hepatic, gastrointestinal (paralytic ileus), or psychiatric disease, as determined by medical history, clinical laboratory tests, electrocardiogram (ECG) results, and physical examination, that will place the subject at risk upon exposure to the study medication or that could confound the analysis and/or interpretation of the study results
- Subjects with evidence of impaired liver/kidney function upon entry into the study defined as aspartate aminotransferase (AST; SGOT), alanine aminotransferase (ALT; SGPT), or alkaline phosphatase levels >3 times the upper limit of normal; gamma glutamyltranspeptidase (GGT or GGTP) ≥ 5 times the upper limit of normal; total bilirubin level outside of the reference range; and/or creatinine level outside of the reference range or >2 mg/dl, or in the investigator's opinion, liver and/or kidney impairment to the extent that the subject should not participate in this study
- Subjects with evidence of significant structural abnormalities of the gastrointestinal tract or any diseases/conditions that affect bowel transit
- Subjects who have required treatment for the diagnosis of irritable bowel syndrome (IBS)
- Subjects receiving hypnotics or other central nervous system (CNS) depressants that, in the investigator's opinion, may pose a risk of additional CNS depression with opioids study medication
- Surgery within 2 months prior to the start of the Screening Period, or planned surgery during the 12-week Double-blind Phase that may have affected GI motility or pain
- Subjects diagnosed with cancer, not including basal cell carcinoma
- Subjects with Rheumatoid Arthritis (RA)
- Subjects receiving opioid substitution therapy for opioid addiction (e.g., methadone or buprenorphine)
- Subjects with active alcohol or drug abuse and/or history of opioid abuse
- Subjects who participated in a clinical research study involving a new chemical entity or an experimental drug within 30 days of study entry (defined as the start of the Screening Period)
- Subjects presently taking, or who had taken naloxone or naltrexone within 30 days of study entry (defined as the start of the Screening Period).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Oxycodone/naloxone prolonged release tablets
Dose strength:5/2.5 mg,10/5mg, 20/10mg,PO,q12h.daily
dose from 10/5mg to 50/25mg.treatment
duration:12 weeks
|
|
Comparatore attivo: Oxycodone prolonged release tablets
Dose strength:5mg,10mg, 20mg,PO,q12h.daily
dose from 10mg to 50mg.treatment duration:12 weeks
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Bowel function index(BFI) 12 Weeks
Lasso di tempo: 12 weeks
|
12 weeks
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
Modified BPI-SF-Average Pain over the last 24 hours
Lasso di tempo: 12 weeks
|
12 weeks
|
Collaboratori e investigatori
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- OXN08-CN-302a
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Non Cancer Pain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
University of OklahomaThe Children's Hospital at OU Medical CenterCompletatoDolore addominale funzionale | Crisi falciforme | Pazienti seguiti dal Pain Team
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
National Cancer Institute (NCI)ReclutamentoKita-kyushu Lung Cancer Antigen 1, umanoStati Uniti
-
Novartis PharmaceuticalsReclutamentoEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaOlanda, Corea, Repubblica di, Spagna, Taiwan, Giappone, Italia, Stati Uniti, Singapore, Canada
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Attivo, non reclutanteCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea, Repubblica di
-
Jonsson Comprehensive Cancer CenterNon ancora reclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Rashmi Verma, MDNational Cancer Institute (NCI)ReclutamentoCarcinoma prostatico resistente alla castrazione | Adenocarcinoma prostatico metastatico | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Assiut UniversityNon ancora reclutamentoDeterminare l’incidenza cumulativa di AKI utilizzando i criteri KDIGO in pazienti pediatrici con tumori maligni presso il South Egypt Cancer Institute (SECI)